TDXD - Is Pembrochemo OK?

There's a school of thought to keep the trial simple, not to ask too many questions in one trial. And it's also a difficult trial to occur because it's 2%. Not everyone gets hurt to testing routinely. So regardless of PD1 expression, maybe the response is going to be slightly lower with single agent IO. That's the thought process at trial design.